



**Queensland
Government**
Queensland Health

Drugs and Poisons: Application by a Medical Practitioner for Approval to Obtain, Possess and Use Amygdalin

Health (Drugs and Poisons) Regulation 1996

(To be completed by the medical practitioner)

Please note that the granting of an approval in response to this application is not an endorsement of treatment with amygdalin by Queensland Health.

Patient Details			
Surname (family name)			
First name (s)			
Address		Postcode	
Date of birth		Male <input type="checkbox"/>	Female <input type="checkbox"/>
Medical practitioner details			
Surname (family name)			
First name (s)		Qualifications	
Address		Postcode
Telephone		Fax	
Clinical details			
Clinical diagnosis (or diagnoses)			

Is the diagnosis histologically proven? Yes No

Is the cancer late stage? Yes No

Is the patient receiving other treatment from an oncologist? Yes No

Has conventional therapy been exhausted? Yes No

Do you accept responsibility for the quality and safety of the preparation you intend to use? Yes No

Have you provided and discussed with the patient the two fact sheets regarding Amygdalin compiled by Queensland Health, to enable the patient's informed consent to treatment? Yes No

I enclose recent relevant specialist oncologist's reports. **(Note: One of the criteria for obtaining approval is that any recent relevant specialist reports must be submitted with the application).** Yes No

Describe the present clinical condition of the patient

.....

.....

Describe the treatment protocol with amygdalin intended to be undertaken

.....

Note: One of the criteria for obtaining approval is the patient provides informed consent to Queensland Health for the use of amygdalin. In order for a patient to give informed consent the medical practitioner must provide the patient with information advising that:

- the process by which the substance is manufactured may not be subject to quality control;
- that the authors of a multi-site clinical trial reported in 1982 concluded that "Amygdalin (Laetrile) is a toxic drug that is not effective as a cancer treatment, and no controlled clinical trials have been conducted";
- its efficacy or usefulness has not been proven; and
- studies have shown that there is a narrow range of safety of amygdalin treatment with regard to cyanide toxicity.

I, acknowledge that, I will provide information to my patient

..... consistent with the above, which will enable my patient to give consent to the proposed treatment and satisfy this criterion for obtaining approval to use amygdalin.

Signature Date:/...../.....